B
Brian J. Bolwell
Researcher at Cleveland Clinic
Publications - 298
Citations - 10110
Brian J. Bolwell is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 49, co-authored 296 publications receiving 9153 citations.
Papers
More filters
Journal ArticleDOI
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
John F. DiPersio,Ivana N. Micallef,Patrick J. Stiff,Brian J. Bolwell,Richard T. Maziarz,Eric D. Jacobsen,Auayporn Nademanee,John M. McCarty,Gary Bridger,Gary Calandra +9 more
TL;DR: Plerixafor and G- CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Journal ArticleDOI
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
Corey Cutler,Stephanie J. Lee,Peter L. Greenberg,H. Joachim Deeg,Waleska S. Pérez,Claudio Anasetti,Brian J. Bolwell,Mitchell S. Cairo,Robert Peter Gale,John P. Klein,Hillard M. Lazarus,Jane L. Liesveld,Philip L. McCarthy,Gustavo Milone,J. Douglas Rizzo,Kirk R. Schultz,Michael E. Trigg,Armand Keating,Daniel J. Weisdorf,Joseph H. Antin,Mary M. Horowitz +20 more
TL;DR: A Markov model constructed to examine 3 transplantation strategies for newly diagnosed MDS found that delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated for low- and intermediate-1-risk patients.
Journal ArticleDOI
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Madan Jagasia,Mukta Arora,Mary E.D. Flowers,Nelson J. Chao,Philip L. McCarthy,Corey Cutler,Alvaro Urbano-Ispizua,Steven Z. Pavletic,Michael Haagenson,Mei-Jie Zhang,Joseph H. Antin,Brian J. Bolwell,Christopher Bredeson,Jean-Yves Cahn,Mitchell S. Cairo,Robert Peter Gale,Vikas Gupta,Stephanie J. Lee,Mark R. Litzow,Daniel J. Weisdorf,Mary M. Horowitz,Theresa Hahn +21 more
TL;DR: Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.
Journal ArticleDOI
Outcome of transplantation for myelofibrosis
Karen K. Ballen,Smriti Shrestha,Kathleen A. Sobocinski,Mei-Jie Zhang,Asad Bashey,Brian J. Bolwell,Francisco Cervantes,Steven M. Devine,Robert Peter Gale,Vikas Gupta,Theresa Hahn,William J. Hogan,Kröger N,Mark R. Litzow,David I. Marks,Richard T. Maziarz,Philip L. McCarthy,Gary J. Schiller,Harry C. Schouten,Vivek Roy,Peter H. Wiernik,Mary M. Horowitz,Sergio Giralt,Mukta Arora +23 more
TL;DR: In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.
Journal ArticleDOI
Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia
Stella M. Davies,Norma K.C. Ramsay,John P. Klein,Daniel J. Weisdorf,Brian J. Bolwell,Jean-Yves Cahn,Bruce M. Camitta,Robert Peter Gale,Sergio Giralt,Carsten Heilmann,P. Jean Henslee-Downey,Roger H. Herzig,Raymond J. Hutchinson,Armand Keating,Hillard M. Lazarus,Gustavo Milone,Steven Neudorf,Waleska S. Pérez,Ray L. Powles,H. Grant Prentice,Gary J. Schiller,Gérard Socié,Marcus R. Vowels,Joseph Wiley,Andrew M. Yeager,Mary M. Horowitz +25 more
TL;DR: Data indicate superior survival with CY/TBI conditioning, compared with Bu/CY conditioning, for HLA-identical sibling bone marrow transplants in children with ALL, according to the International Bone Marrow Transplant Registry.